Martin Aringer

36.2k total citations · 1 hit paper
232 papers, 7.5k citations indexed

About

Martin Aringer is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Martin Aringer has authored 232 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Rheumatology, 76 papers in Immunology and 52 papers in Pathology and Forensic Medicine. Recurrent topics in Martin Aringer's work include Systemic Lupus Erythematosus Research (109 papers), Rheumatoid Arthritis Research and Therapies (50 papers) and Monoclonal and Polyclonal Antibodies Research (42 papers). Martin Aringer is often cited by papers focused on Systemic Lupus Erythematosus Research (109 papers), Rheumatoid Arthritis Research and Therapies (50 papers) and Monoclonal and Polyclonal Antibodies Research (42 papers). Martin Aringer collaborates with scholars based in Germany, Austria and United States. Martin Aringer's co-authors include Josef S Smolen, W. Graninger, G Steiner, Hendrik Schulze‐Koops, Sindhu R. Johnson, Josef S Smolen, Andrew P. Cope, John J. O’Shea, Nicolas Rohleder and Matthias Boentert and has published in prestigious journals such as New England Journal of Medicine, Blood and The Journal of Immunology.

In The Last Decade

Martin Aringer

215 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trial of Tocilizumab in Giant-Cell Arteritis

2017 815 citations John H. Stone, Katie Tuckwell et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Martin Aringer

Since Specialization

Citations

This map shows the geographic impact of Martin Aringer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Aringer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Aringer more than expected).

Fields of papers citing papers by Martin Aringer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Aringer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Aringer. The network helps show where Martin Aringer may publish in the future.

Co-authorship network of co-authors of Martin Aringer

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Aringer. A scholar is included among the top collaborators of Martin Aringer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Aringer. Martin Aringer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Type I interferon limits interleukin-6 signalling in SLE through shedding interleukin-6 receptors 2025 ·Lara D. Veeken ·(unknown), Erik Klapproth, (unknown), Christoph Becker‐Pauly, Sebastian Zeißig, (unknown), (unknown), (unknown), Nicolai Leuchten, Stefan Rose‐John, Ali El‐Armouche, Adelheid Korb‐Pap, Martin Aringer	0
2	Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases 2024 ·RMD Open ·Martin Aringer, Oliver Distler, Anna‐Maria Hoffmann‐Vold, Masataka Kuwana, Helmut Prosch, Elizabeth R. Volkmann	4
3	VEXAS syndrome: complete molecular remission after hypomethylating therapy 2024 ·Annals of Hematology ·Katja Sockel, Katharina S. Götze, Christina Ganster, Marius Bill, (unknown), Ekaterina Balaian, Martin Aringer, Karolin Trautmann‐Grill, (unknown), Martin Bornhäuser, Detlef Haase, Christian Thiede	18
4	Severe methotrexate toxicity in elderly patients under diuretics 2024 ·RMD Open ·(unknown), Matthias Kühn, Kristine Herrmann, Nicolai Leuchten, Martin Aringer	2
5	POS1090 IMPLEMENTATION OF QUALITY STANDARDS FOR HEALTH CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS: FIRST RESULTS FROM THE NATIONAL DATABASE OF THE GERMAN COLLABORATIVE ARTHRITIS CENTRES 2023 ·Annals of the Rheumatic Diseases ·Katinka Albrecht, K. Thiele, Martin Aringer, Johanna Callhoff, Kirsten Karberg, Klaus Krueger, (unknown), Hannes Lorenz, Martín Rudwaleit, (unknown), Matthias Schneider, (unknown), Christof Specker, (unknown), Jürgen Braun, Uta Kiltz	1
6	Assessment-Tools für den systemischen Lupus erythematodes 2023 ·Zeitschrift für Rheumatologie ·Martin Aringer, Nicolai Leuchten	2
7	Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA) 2022 ·Journal of Clinical Medicine ·(unknown), Ann Christina Foldenauer, (unknown), Rieke Alten, Martin Aringer, Marina Backhaus, Gerd R Burmester, Eugen Feist, Herbert Kellner, Klaus Krueger, Ulf Müller‐Ladner, Andrea Rubbert‐Roth, Hans‐Peter Tony, Siegfried Wassenberg, Harald Burkhardt, Frank Behrens	1
8	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients 2021 ·Annals of the Rheumatic Diseases ·(unknown), Myrto Kostopoulou, Dionysis Nikolopoulos, (unknown), (unknown), Laura Andréoli, Martin Aringer, John Boletis, Andrea Doria, Frédéric Houssiau, David Jayne, Marta Mosca, Elisabet Svenungsson, Anǵela Tincani, George Βertsias, Antonis Fanouriakis, Dimitrios T. Boumpas	11
9	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria 2018 ·The Journal of Rheumatology ·Sindhu R. Johnson, Dinesh Khanna, David Daikh, Ricard Cervera, N. Costedoat‐Chalumeau, Dafna D. Gladman, Bevra H. Hahn, Falk Hiepe, Jorge Sánchez‐Guerrero, Elena Massarotti, Dimitrios T. Boumpas, Karen H. Costenbader, David Jayne, Thomas Dörner, Diane L. Kamen, Marta Mosca, Rosalind Ramsey‐Goldman, Josef S Smolen, David Wofsy, Martin Aringer	30
10	Trial of Tocilizumab in Giant-Cell Arteritis breakdown → 2017 ·New England Journal of Medicine ·John H. Stone, Katie Tuckwell, Sophie Dimonaco, Micki Klearman, Martin Aringer, Daniël Blockmans, Elisabeth Brouwer, María C. Cid, Bhaskar Dasgupta, Jürgen Rech, Carlo Salvarani, Georg Schett, Hendrik Schulze‐Koops, Robert Spiera, Sebastian Unizony, Neil Collinson	815
11	Relevant Concepts of Functioning for Patients With Systemic Lupus Erythematosus Identified in a Delphi Exercise of Experts and a Literature Review 2014 ·Arthritis Care & Research ·Nicolai Leuchten, (unknown), (unknown), Tanja Stamm, Josef S Smolen, David S. Pisetsky, Martin Aringer	5
12	Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today. 2013 ·PubMed ·(unknown), (unknown), (unknown), Karsten Conrad, (unknown), Martin Aringer	7
13	A 3-Day Delay in Synovial Fluid Crystal Identification Did Not Hinder the Reliable Detection of Monosodium Urate and Calcium Pyrophosphate Crystals 2013 ·JCR Journal of Clinical Rheumatology ·Anne‐Kathrin Tausche, S. Gehrisch, (unknown), Maria Winzer, Ursula Range, Stefan R. Bornstein, Gabriele Siegert, Carsten Wunderlich, Martin Aringer	17
14	Innate immune processes in lupus erythematosus 2012 ·Clinical Immunology ·Martin Aringer, Claudia Günther, Min Ae Lee‐Kirsch	25
15	Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: An open‐label study 2004 ·Arthritis & Rheumatism ·Martin Aringer, W. Graninger, G Steiner, Josef S Smolen	256
16	Characterization and Analysis of the Proximal Janus Kinase 3 Promoter 2003 ·The Journal of Immunology ·Martin Aringer, Sigrun R. Hofmann, David M. Frucht, Min Chen, Michael Centola, Akio Morinobu, Roberta Visconti, Daniel L. Kastner, Josef S Smolen, John J. O’Shea	26
17	SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. 2003 ·Arthritis Research ·Martin Aringer, Josef S Smolen	87
18	Stat4 Is Expressed in Activated Peripheral Blood Monocytes, Dendritic Cells, and Macrophages at Sites of Th1-Mediated Inflammation 2000 ·The Journal of Immunology ·David M. Frucht, Martin Aringer, Jérôme Galon, Carol L. Danning, M. Brown, Samuel Fan, Michael Centola, Changyou Wu, (unknown), Hani El‐Gabalawy, John J. O’Shea	160
19	Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes 2000 ·The Journal of Immunology ·Denis Franchimont, Jérôme Galon, Massimo Gadina, Roberta Visconti, Yong Zhou, Martin Aringer, David M. Frucht, George P. Chrousos, John J. O’Shea	210
20	Osteopathien nach Lungentransplantation 1999 ·Journal für Kardiologie (Krause & Pachernegg GmbH) ·Martin Aringer, Peter Pietschmann	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact